Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

Comprehensive heart teams are rewriting the rules of patient care

Multidisciplinary heart teams are growing more and more popular among hospitals and health systems all over the world. What started as a way to select TAVR patients has become something much more important. 

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

TAVR and PAD: What cardiologists need to know

TAVR patients presenting with peripheral artery disease face significantly higher in-hospital risks, according to a new study published in Current Problems in Cardiology

Samir Kapadia, MD, chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at Cleveland Clinic, explains why he believes the results of the late-breaking PROTECTED TAVR testing the use of a TAVR cerebral protection device were positive, although it did not meet its primary endpoint.

VIDEO: Exploring the use of cerebral protection devices during TAVR

Samir Kapadia, MD, chair of the department of cardiovascular medicine at Cleveland Clinic, shared his perspective on the use of cerebral protection devices during TAVR procedures. 

Thumbnail

Why are post-TAVR stroke rates higher at comprehensive stroke centers?

One of the more likely reasons is simple: specialty centers have better tools for identifying signs of stroke.

A team in China treated 10 patients—split evenly between men and women—with the SinoCrown TAVR valve developed by Lepu Medical Technology Company. The average patient age was 77.5 years old.

New self-expanding TAVR valve shows promise

It is still early for this new-look TAVR valve, but initial findings out of China include a procedural success rate of 100% and no deaths, disabling strokes or myocardial infarctions after 30 days. Read a full analysis from the team using the device. 

Thumbnail

An updated look at surgically repairing the mitral valve due to mitral regurgitation

A team of cardiologists and cardiac surgeons collaborated on the new analysis, reviewing data from more than 50,000 patients and developing a new risk model for clinicians.  

Abbott has gained U.S. Food and Drug Administration (FDA) approval for its Navitor transcatheter aortic valve replacement (TAVR) system, the company’s new self-expanding valve for high-risk patients with severe symptomatic aortic stenosis.

Abbott receives FDA approval for new self-expanding TAVR system

The device, which gained CE mark approval in Europe in May 2021, features a new-look fabric cuff designed to keep the risk of paravalvular leak (PVL) at a minimum.

How intravascular lithotripsy can improve TMVR outcomes

The IVL technology developed by Shockwave Medical helped clinicians treat a TMVR patient who had previously undergone TAVR. Could this be a common use of IVL in the future?

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.